製品名:(R)-4-(2,4-dimethoxybenzyl)-3-methylpiperazin-2-one

IUPAC Name:(3R)-4-[(2,4-dimethoxyphenyl)methyl]-3-methylpiperazin-2-one

CAS番号:1383146-20-0
分子式:C14H20N2O3
純度:95%
カタログ番号:CM131538
分子量:264.33

包装単位 有効在庫 価格(USD) 数量
CM131538-100mg in stock Əƻ
CM131538-250mg in stock ȀňǕ
CM131538-1g in stock ǕŔŔ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:1383146-20-0
分子式:C14H20N2O3
融点:-
SMILESコード:O=C1NCCN(CC2=CC=C(OC)C=C2OC)[C@@H]1C
密度:
カタログ番号:CM131538
分子量:264.33
沸点:436.1±45.0°C at 760 mmHg
MDL番号:MFCD22372628
保管方法:Store at room temperature.

Category Infos

Piperazines
Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.

Column Infos

Fezolinetant
Dec 10, 2023, VEOZA (fezolinetant) approved by European Commission for treatment of vasomotor symptoms associated with menopause.
VEOZAH is the first and only neurokinin 3 (NK3) receptor antagonist that blocks NKB from binding on KNDy neurons to help reduce heat signals that trigger VMS. First-in-class fezolinetant brings women a new nonhormonal therapy for hot flashes.
In May 2023, FDA has approved VEOZA(fezolinetant) 45 mg once daily for the treatment of moderate to severe VMS due to menopause.

Related Products